BI 754091

Drug Profile

BI 754091

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 May 2017 Boehringer Ingelheim plans a phase I trial of BI 754091 in combination with BI 754111 for Cancer in USA (NCT03156114)
  • 31 Oct 2016 Boehringer Ingelheim plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA and Canada (Parenteral) (NCT02952248)
  • 29 Sep 2016 Boehringer Ingelheim and Sarah Cannon Research Institute enter into a collaboration agreement to develop BI 754091 and BI 754111 for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top